PPAR - Loving Living Local ...

Table 1 Selected PPAR-targeted drugs in Phase II or III trials * Full size table Many research groups have “been fishing with the wrong bait” in trying to develop effective and safe anti ...

Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease ...

The growing challenge in cancer therapy lies in overcoming tumor heterogeneity, drug resistance, and associated side effects.

The European Commission (EC) has conditionally approved Ipsen’s Iqirvo (elafibranor) for the treatment of primary biliary ...

A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...

Kayfanda (odevixibat) is labelled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

9月11日，上海交通大学医学院附属瑞金医院王卫庆、王计秋团队在顶级期刊《Nature》上发文，研究发现大脑能够通过“脑-肠轴”通道直接调控肠道的脂肪吸收，同时确定了葛根提取物— 葛根素 ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...